BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Share Circulation

Deep News

02/09

BIOSTAR PHARM-B (02563) announced that the company has received a filing notice issued by the China Securities Regulatory Commission (CSRC) on February 5, 2026. According to the notice, the company has completed the filing with the CSRC regarding the implementation of an H-share full circulation arrangement. The filing notice will remain valid for 12 months from the date of issuance. The company will apply to the Stock Exchange for the conversion and listing of the shares.

As of the date of this announcement, specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing in accordance with the Listing Rules and applicable laws at the appropriate time.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1119636136"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119636136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119636136?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119636136","market":"sh","top_or_hot":-1,"title":"BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Share Circulation","media":"Deep News","content":"<p>BIOSTAR PHARM-B (02563) announced that the company has received a filing notice issued by the China Securities Regulatory Commission (CSRC) on February 5, 2026. According to the notice, the company has completed the filing with the CSRC regarding the implementation of an H-share full circulation arrangement. The filing notice will remain valid for 12 months from the date of issuance. The company will apply to the Stock Exchange for the conversion and listing of the shares.</p>\n<p>As of the date of this announcement, specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing in accordance with the Listing Rules and applicable laws at the appropriate time.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Share Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOSTAR PHARM-B Receives CSRC Filing Notice for Full Share Circulation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-02-09 08:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BIOSTAR PHARM-B (02563) announced that the company has received a filing notice issued by the China Securities Regulatory Commission (CSRC) on February 5, 2026. According to the notice, the company has completed the filing with the CSRC regarding the implementation of an H-share full circulation arrangement. The filing notice will remain valid for 12 months from the date of issuance. The company will apply to the Stock Exchange for the conversion and listing of the shares.</p>\n<p>As of the date of this announcement, specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing in accordance with the Listing Rules and applicable laws at the appropriate time.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"華昊中天醫藥-B","start_time":0,"source_url":"","article_id":"1119636136","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119636136","pubTimestamp":1770597152,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"BIOSTAR PHARM-B (02563) announced that the company has received a filing notice issued by the China Securities Regulatory Commission (CSRC) on February 5, 2026. According to the notice, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","02563":"华昊中天医药-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"映泰医药-B收到证监会股票全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02563":1,"09939":1},"content_text":"BIOSTAR PHARM-B (02563) announced that the company has received a filing notice issued by the China Securities Regulatory Commission (CSRC) on February 5, 2026. According to the notice, the company has completed the filing with the CSRC regarding the implementation of an H-share full circulation arrangement. The filing notice will remain valid for 12 months from the date of issuance. The company will apply to the Stock Exchange for the conversion and listing of the shares.\nAs of the date of this announcement, specific details of the implementation plan for the conversion and listing have not been finalized. The company will issue further announcements regarding the progress and details of the conversion and listing in accordance with the Listing Rules and applicable laws at the appropriate time.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}